Background: Proportions of patients dying from the coronavirus disease-19 (COVID-19) vary between different countries. We report the characteristics; clinical course and outcome of patients requiring intensive care due to COVID-19 induced acute respiratory distress syndrome (ARDS). Methods: This is a retrospective, observational multicentre study in five German secondary or tertiary care hospitals. All patients consecutively admitted to the intensive care unit (ICU) in any of the participating hospitals between March 12 and May 4, 2020 with a COVID-19 induced ARDS were included. Results: A total of 106 ICU patients were treated for COVID-19 induced ARDS, whereas severe ARDS was present in the majority of cases. Survival of ICU treatment was 65.0%. Median duration of ICU treatment was 11 days; median duration of mechanical ventilation was 9 days. The majority of ICU treated patients (75.5%) did not receive any antiviral or anti-inflammatory therapies. Venovenous (vv) ECMO was utilized in 16.3%. ICU triage with population-level decision making was not necessary at any time. Univariate analysis associated older age, diabetes mellitus or a higher SOFA score on admission with non-survival during ICU stay. Conclusions: A high level of care adhering to standard ARDS treatments lead to a good outcome in critically ill COVID-19 patients.
Background: Proportions of patients dying from the coronavirus disease-19 (COVID-19) vary between different countries. We report the characteristics; clinical course and outcome of patients requiring intensive care due to COVID-19 induced acute respiratory distress syndrome (ARDS). Methods: This is a retrospective, observational multicentre study in five German secondary or tertiary care hospitals. All patients consecutively admitted to the intensive care unit (ICU) in any of the participating hospitals between March 12 and May 4, 2020 with a COVID-19 induced ARDS were included. Results: A total of 106 ICU patients were treated for COVID-19 induced ARDS, whereas severe ARDS was present in the majority of cases. Survival of ICU treatment was 65.0%. Median duration of ICU treatment was 11 days; median duration of mechanical ventilation was 9 days. The majority of ICU treated patients (75.5%) did not receive any antiviral or anti-inflammatory therapies. Venovenous (vv) ECMO was utilized in 16.3%. ICU triage with population-level decision making was not necessary at any time. Univariate analysis associated older age, diabetes mellitus or a higher SOFA score on admission with non-survival during ICU stay. Conclusions: A high level of care adhering to standard ARDS treatments lead to a good outcome in critically illCOVID-19patients.
Authors: Michael J Kratochvil; Gernot Kaber; Sally Demirdjian; Pamela C Cai; Elizabeth B Burgener; Nadine Nagy; Graham L Barlow; Medeea Popescu; Mark R Nicolls; Michael G Ozawa; Donald P Regula; Ana E Pacheco-Navarro; Samuel Yang; Vinicio A de Jesus Perez; Harry Karmouty-Quintana; Andrew M Peters; Bihong Zhao; Maximilian L Buja; Pamela Y Johnson; Robert B Vernon; Thomas N Wight; Carlos E Milla; Angela J Rogers; Andrew J Spakowitz; Sarah C Heilshorn; Paul L Bollyky Journal: JCI Insight Date: 2022-06-22
Authors: Michael J Kratochvil; Gernot Kaber; Sally Demirdjian; Pamela C Cai; Elizabeth B Burgener; Nadine Nagy; Graham L Barlow; Medeea Popescu; Mark R Nicolls; Michael G Ozawa; Donald P Regula; Ana E Pacheco-Navarro; Samuel Yang; Vinicio A de Jesus Perez; Harry Karmouty-Quintana; Andrew M Peters; Bihong Zhao; Maximilian L Buja; Pamela Y Johnson; Robert B Vernon; Thomas N Wight; Carlos E Milla; Angela J Rogers; Andrew J Spakowitz; Sarah C Heilshorn; Paul L Bollyky Journal: medRxiv Date: 2022-04-04